CD226 and cancer: Finally, antibodies directed to the immune checkpoint molecules TIGIT and CD226 (DNAM-1), inhibitory receptors CD85j and CD161, and activating receptor CD314 were added as they modulate NK cell functionality and are potential targets of cancer immunotherapies (43–49).